Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Sharon Hemond Hrynkow, insider at Cyclo Therapeutics

Sharon Hemond Hrynkow Insider Information

Insider of Cyclo Therapeutics
Dr. Hrynkow joined the Company in September 2015.  Prior to joining Cyclo Therapeutics, Dr. Hrynkow served in a range of leadership roles in global health at the National Institutes of Health (NIH), including as Deputy Director and Acting Director of the Fogarty International Center, Associate Director of the National Institute on Environmental Health Sciences, and Senior Advisor to the NIH Deputy Director.  She also made seminal contributions in the fight against HIV/AIDS during her early federal service at the Department of State.  In 2012, Dr. Hrynkow became the inaugural President of the Global Virus Network, a non-profit organization working to combat pandemic viral disease.

A developmental neuroscientist by training, Dr. Hrynkow has worked passionately for decades to advance science for the benefit of society, to now include her work at Cyclo Therapeutics to bring Trappsol® Cyclo™ to market approval for the benefit of patients suffering from Niemann-Pick Disease type C and Alzheimer’s Disease. She is frequently asked to serve on national and international advisory committees, and has served on the President’s Council of Advisors for Science and Technology, American Association for the Advancement of Science Committee on Science, Engineering and Public Policy (also as Chair) and the U.S. National Academies of Science, Engineering and Medicine’s Division of Earth and Life Sciences advisory committee.  She has been recognized for her contributions to global health and global science through prestigious awards, including with the US President’s Merit Award for Senior Executives, the Order of Merit from the King of Norway, and as an elected Fellow of the American Association for the Advancement of Science and as an elected member of the Council on Foreign Relations.

What is Sharon Hemond Hrynkow's net worth?

The estimated net worth of Sharon Hemond Hrynkow is at least $36,333.00 as of March 29th, 2021. Dr. Hrynkow owns 18,350 shares of Cyclo Therapeutics stock worth more than $36,333 as of May 22nd. This net worth approximation does not reflect any other assets that Dr. Hrynkow may own. Learn More about Sharon Hemond Hrynkow's net worth.

What is Sharon Hemond Hrynkow's salary?

As the Insider of Cyclo Therapeutics, Inc., Dr. Hrynkow earned a total compensation package of $297,855.00 in 2020. Dr. Hrynkow earned a salary of $248,000.00, and other compensation of $49,855.00. Learn More on Sharon Hemond Hrynkow's salary.

How do I contact Sharon Hemond Hrynkow?

The corporate mailing address for Dr. Hrynkow and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected] Learn More on Sharon Hemond Hrynkow's contact information.

Has Sharon Hemond Hrynkow been buying or selling shares of Cyclo Therapeutics?

Sharon Hemond Hrynkow has not been actively trading shares of Cyclo Therapeutics over the course of the past ninety days. As an example of a recent trade by , 0 shares of the company's stock in a transaction on Sunday, May 22nd. Learn More on Sharon Hemond Hrynkow's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 17 times. They purchased a total of 70,754 shares worth more than $297,326.22. The most recent insider tranaction occured on May, 16th when COO Jeffrey Tate bought 3,000 shares worth more than $6,360.00. Insiders at Cyclo Therapeutics own 12.3 % of the company. Learn More about insider trades at Cyclo Therapeutics.

Information on this page was last updated on 5/16/2022.

Sharon Hemond Hrynkow Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2021Buy1,000$4.98$4,980.00View SEC Filing Icon  
3/29/2021Buy1,000$7.46$7,460.0018,350View SEC Filing Icon  
3/29/2021Buy1,000$7.46$7,460.0018,350View SEC Filing Icon  
See Full Table

Sharon Hemond Hrynkow Buying and Selling Activity at Cyclo Therapeutics

This chart shows Sharon Hemond Hrynkow's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Read More

Today's Range

Now: $1.98
Low: $1.95
High: $2.10

50 Day Range

MA: $2.68
Low: $1.98
High: $3.21

2 Week Range

Now: $1.98
Low: $1.88
High: $13.00

Volume

26,605 shs

Average Volume

26,192 shs

Market Capitalization

$16.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.